Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | FBP1 | P09467 | 2/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.43 |
| ▸ | F2RL3 | Q96RI0 | 3/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PON1 | P27169 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29594055 | 1.00 | NPC1 (0.48) | NPC1RAB9AGFERFBP1TRPV1 | |
| SCHEMBL31208289 | 0.82 | KDM4E (0.42) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL1705418 | 0.82 | KDM4E (0.42) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| Methane SCHEMBL11094670 | 0.81 | HDAC3 (0.43) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL4399183 | 0.80 | L3MBTL1 (0.53) | NPC1RAB9AGFERFBP1TRPV1 | |
| SCHEMBL2706413 | 0.80 | NPC1 (0.49) | NPC1RAB9AGFERFBP1TRPV1 | |
| SCHEMBL23095285 | 0.79 | NPC1 (0.48) | NPC1RAB9AGFERFBP1TRPV1 | |
| SCHEMBL3068277 | 0.79 | FBP1 (0.50) | NPC1RAB9AGFERFBP1TRPV1 | |
| SCHEMBL179531 | 0.79 | MAPT (0.56) | NPC1RAB9AGFERFBP1TRPV1 | |
| SCHEMBL10045295 | 0.79 | NPC1 (0.51) | NPC1RAB9AGFERFBP1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113185511-B | Pyrimidine compound and preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2022-04-26 | — | — | CN | disclosed |
| CN-113185511-A | Pyrimidine compound and preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2021-07-30 | — | — | CN | disclosed |
| US-9156834-B2 | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2015-10-13 | — | — | US | disclosed |
| US-9156834-B2 | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2015-10-13 | — | — | US | disclosed |
| US-9156834-B2 | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2015-10-13 | — | — | US | disclosed |
| US-20140357624-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PF MEDICAMENT (FR) | 2014-12-04 | — | — | US | disclosed |
| US-20140357624-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PF MEDICAMENT (FR) | 2014-12-04 | — | — | US | disclosed |
| US-20140357624-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PF MEDICAMENT (FR) | 2014-12-04 | — | — | US | disclosed |
| US-8846930-B2 | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8846930-B2 | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2014-09-30 | — | — | US | disclosed |
| US-20130172326-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PIERRE FABRE MEDICAMENT (FR) | 2013-07-04 | — | — | US | disclosed |
| US-20130172326-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PIERRE FABRE MEDICAMENT (FR) | 2013-07-04 | — | — | US | disclosed |
| WO-2012069503-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PIERRE FABRE MEDICAMENT (FR) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012069503-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PIERRE FABRE MEDICAMENT (FR) | 2012-05-31 | — | — | WO | disclosed |
| US-20100261708-A1 | Diazepane Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| EP-2215080-A1 | DIAZEPANE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009055357-A1 | DIAZEPANE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009055357-A1 | DIAZEPANE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | WO | disclosed |
| US-4168982-A | Photopolymerizable compositions containing nitroso dimers to selectively inhibit thermal polymerization | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1979-09-25 | — | — | US | disclosed |
| US-4009040-A | DEPOLYMERIZATION TO FORM POSITIVE IMAGES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172326-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | KCNA4, KCNA1, KCNB1 | NPC1 832/4885RAB9A 2024/4885GFER 622/4885 |
| US-20100261708-A1 | Diazepane Compounds Which Modulate The CB2 Receptor | CNR1, CNR2, BDKRB2 | NPC1 1695/4885RAB9A 3016/4885GFER 3118/4885 |
| US-20140357624-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | KCNA4, KCNA1, KCNB1 | NPC1 832/4885RAB9A 2024/4885GFER 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.